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Evaluation of Effectiveness and Cost-Effectiveness of a Clinical
Decision Support System in Managing Hypertension in Resource
Constrained Primary Health Care Settings: Results From a Cluster
Randomized Trial
Raghupathy Anchala, MD, PhD; Stephen Kaptoge, PhD; Hira Pant, MA; Emanuele Di Angelantonio, MD, PhD; Oscar H. Franco, MD, PhD;
D. Prabhakaran, MD, DM, MSc
Background-—Randomized control trials from the developed world report that clinical decision support systems (DSS) could
provide an effective means to improve the management of hypertension (HTN). However, evidence from developing countries in
this regard is rather limited, and there is a need to assess the impact of a clinical DSS on managing HTN in primary health care
center (PHC) settings.
Methods and Results-—We performed a cluster randomized trial to test the effectiveness and cost-effectiveness of a clinical DSS
among Indian adult hypertensive patients (between 35 and 64 years of age), wherein 16 PHC clusters from a district of Telangana
state, India, were randomized to receive either a DSS or a chart-based support (CBS) system. Each intervention arm had 8 PHC
clusters, with a mean of 102 hypertensive patients per cluster (n=845 in DSS and 783 in CBS groups). Mean change in systolic blood
pressure (SBP) from baseline to 12 months was the primary endpoint. The mean difference in SBP change from baseline between
the DSS and CBS at the 12th month of follow-up, adjusted for age, sex, height, waist, body mass index, alcohol consumption,
vegetable intake, pickle intake, and baseline differences in blood pressure, was 6.59 mm Hg (95% conﬁdence interval: 12.18 to
1.42; P=0.021). The cost-effective ratio for CBS and DSS groups was $96.01 and $36.57 per mm of SBP reduction, respectively.
Conclusion-—Clinical DSS are effective and cost-effective in the management of HTN in resource-constrained PHC settings.
Clinical Trial Registration-—URL: http://www.ctri.nic.in. Unique identiﬁer: CTRI/2012/03/002476. ( J Am Heart Assoc. 2015;4:
e001213 doi: 10.1161/JAHA.114.001213)
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D ecision support systems (DSS) have been deﬁned astools that help clinicians decide on a course of action in
response to an understanding of the patient’s status. Recent
studies from the developed world report that DSS provide an
effective means to improve the physician performance.1–4 An
improvement in quality of antihypertensive treatment, con-
currently leading to a considerable reduction in drug costs,
has also been shown for DSS.5 Randomized control trials
from the developed world report that DSS provide an
effective means to improve the management of hypertension
(HTN).2,5–9 However, evidence from developing countries in
this regard is rather limited. An increasing penetration of
information technology in noncommunicable diseases health
domain in India,10,11 and a shortage of primary health care
workforce conversant with guideline-based clinical manage-
ment,12 are opportune reasons to ﬁnd answers for a pertinent
question: Are DSS effective in managing hypertension in
resource constrained primary health center (PHC) settings?
Systematic reviews on DSS, as an intervention, report a
paucity of studies on patient outcomes for cardiovascular
disease (CVD) in the Western world.3,13,14 The potential role
of DSS for the management of blood pressure (BP) among
low- and middle-income countries remains unclear. In a
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resource-constrained setting such as a PHC, the implemen-
tation of a DSS intervention should test not only the physician
performance, but also on related patient outcomes. Individual
randomization dilutes the intervention effect size owing to
contamination between individuals.15 Diffuse and complex
interventions such as DSS (having information technology
inputs) need cluster randomization.16 Moreover, coefﬁcient of
variation (CV) between PHC clusters can only be accounted
for by analyzing cluster-level data. Hence, we performed a
cluster randomized trial that aimed to test the effectiveness
and cost-effectiveness of DSS for BP management among
Indian hypertensive patients.
Methods
Study Design
We performed a cluster randomized trial to test the
effectiveness and cost-effectiveness of a DSS among Indian
hypertensive patients, wherein PHC clusters were randomized
to receive either a DSS or a chart-based support (CBS) system
in a district of Telangana state, India (baseline vs. 12-month
follow-up; 8 PHC clusters per intervention). The processes
involved in development, validation, and pilot testing of the
DSS have been previously described.17
Intervention
The process of development and validation of our clinical DSS
for management of HTN have been previously published.17
Physicians from the PHCs, who were randomized to receive
the DSS arm, were trained and instructed to follow the
algorithms and prompts that would arise out of the computer-
based software for management of BP. DSS was a software
that helped the physician to (1) undertake a thorough
evaluation of risk factors that hypertensive patients may have
for developing a CVD; (2) classify the risk level based on data
entered by the physician. These included lifestyle-related risk
factors, such as tobacco use, unhealthy diet (high salt intake),
obesity (waist circumference >90 cm in men and >80 cm in
women), and physical inactivity (physical activity less than
30 minutes a day for at least 5 days in a week); nonmodi-
ﬁable risk factors, such as age >55 years in males and
>65 years in females, family history of premature coronary
artery disease (males <55 years, female >65 years), history
of heart disease (heart attack, angina, heart failure [HF], or
any surgical procedure on coronary vessels, ie, coronary
artery bypass graft surgery or percutaneous transluminal
coronary angioplasty), history of stroke or transient ischemic
attack, history of diabetes, high levels low-density lipoprotein
(>100 mg/dL), low levels of high-density lipoprotein in blood
(<40 mg/dL), and hypertriglyceridemia (≥150 mg/d:); (3)
follow a software-prompted algorithmic guideline-based drug
management (which was developed based on Indian hyper-
tension guidelines II [2007])18; and (4) give alerts on the
counseling on lifestyle changes and adherence to medication.
Only lifestyle-related counseling was provided for patients
suffering from comorbid conditions, such as hyperlipidemia
and diabetes, in the primary care centers. However, all
patients suffering from any other comorbid conditions were
referred to secondary care centers (community health
centers) for their disease management. The algorithm had a
deﬁned set of criteria for referral to a higher center in the HTN
treatment algorithms (Table S1).
The DSS was installed in a netbook and given to the
physicians in the DSS group. All the physicians allocated to
the DSS group had given a written informed consent to enter
all the study patients’ data in the netbook (containing the DSS
software) and view the DSS recommendations. However, they
had the choice to agree or disagree with the DSS recom-
mendations. The ﬁnal summary output sheet containing the
patient-tailored recommendations (based on the data entered
by the physician) in the DSS had a tracking variable, which
speciﬁcally asked the treating physician to document their
agreement or disagreement with the DSS recommendations
and, if agreeable, whether they implemented or did not
implement the suggested recommendations. The physicians
randomized to receive the CBS had the guidelines and lifestyle
advices printed as a poster format, which was ﬁxed to the wall
opposite the place where the physician usually sat and
examined the patients in the outpatient department. Posters
were displayed prominently and were visible even at a
distance of 3 m. The risk factors that need to be speciﬁcally
elicited, classiﬁcation of risk among hypertensive subjects,
ﬂow chart for drug management, and advice for lifestyle
interventions was included as a simple ﬂow chart in the form
of a poster.
Study Endpoints
The primary endpoint was to compare the systolic blood
pressure (SBP) at 0 and 12 months among hypertensive
patients randomized to receive either the DSS or the CBS
group. The secondary endpoints were to compare the cost-
effectiveness of the DSS versus the CBS at the end of
12 months among hypertensive patients.
Study Participants
Adult male and female Indians in the age group of 35 to
64 years, with SBP of 140 mm Hg or greater and/or diastolic
blood pressure (DBP) of 90 mm Hg or greater (irrespective of
antihypertensive medications) who had given an informed
written consent form were included in the study. Hypertensive
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subjects who have been hospitalized within the last
12 months, pregnant and lactating women, and participants
with a history of cancer (physician certiﬁed) were excluded.
The study protocol was approved by the (1) Human Biology
Research Ethics Committee, University of Cambridge, UK, and
(2) Institutional Ethics Committee, Public Health Foundation
of India, New Delhi, India. Written informed consent was
obtained from both the physicians and patients who volun-
teered to take part in the study. Figure 1 depicts the consort
ﬂow chart, which details the number of participants from each
PHC cluster.
Study Settings
The study site, Mahabubnagar district, belongs to the state
of Telangana, India (latitude between 15°550 and 17°290N;
longitude between 77°150 and 79°150E) and has an area of
18 432 km2.19 We chose Mahabubnagar district because it
has been identiﬁed as one of the backward districts
(regional imbalances in development and health indicators)
of Telangana State by the Backward Regions Grant Fund,
Ministry of Panchayat Raj, Government of India.20 Moreover,
Mahabubnagar had low health infrastructure and lack of
qualiﬁed and trained staff for managing the PHCs. Because
our intervention was aimed to improve the capacity of the
existing primary health care workforce conversant with
guideline-based clinical management, we chose Mahabubna-
gar district.
Sample-Size Calculations
To detect a difference of 5 mm Hg SBP, the individual
randomization sample size was calculated at 239 subjects
per intervention arm (SD, 19.5 mm21), with 80% power and
an alpha of 0.05. Because cluster randomization was
attempted in this study, the individual randomization sample
size was adjusted by a design effect of 2.98 (design
effect=1+[size of cluster1]9intracluster correlation [ICC]).
The ICC for the clusters among the Mahabubnagar district,
AP, India (study site), was calculated to be 0.02 (based on the
Indian sentinel surveillance study done on a representative
sample from 10 sites in India).21 Hence, the cluster-adjusted
sample size was 713 hypertensive patients per intervention
arm to detect a 5 mm Hg difference in SBP with a power of
80% and an alpha of 0.05. After adjusting for the CV among
the various clusters (CV=0.25), the sample size per interven-
Assessed for eligibility (n= 2478)Enrollment
Excluded (n= 840)
• Not meeting inclusion criteria (n= 521)
• Declined to participate (n= 319 )
Randomized (n= 1638)
Allocated to DSS group – 8 PHCs
Cluster size for each PHC: 107, 112, 98, 96, 
149 70 105 d 108 ti l t t l 845
Allocated to CBS group – 8 PHCs
Cluster size for each PHC: 99, 105, 101, 102, 
Allocation
, ,  an  respec ve y; o a  n=  
hypertensive patients. Received allocated 
intervention (n=840); did not receive allocated 
intervention (patient loss due to seasonal 
migration) (n= 5)
102, 100, 88, 96 respectively; total 793 
hypertensive patients. Received allocated 
intervention (n=783); did not receive allocated 
intervention (patient loss due to seasonal 
migration) (n=10 )
Lost to follow-up (migration) (n= 64) Lost to follow-up (migration) (n= 7)Follow-Up
• MITT analysis (n= 840) : Excluded from 
analysis (did not receive allocated 
intervention: n= 5  
MITT analysis (n= 783) : Excluded from 
analysis (did not receive allocated 
n= 10)
Analysis
)
• ITT was also performed subsequently by 
including the 5 patients who did not receive 
the intervention
DSS – decision support system; CBS – Chart Based Support system; MITT – Modified intention to treat; ITT – Intention to treat
intervention:   
• ITT was also performed subsequently by 
including the 10 patients who did not receive 
the intervention
Figure 1. Consort ﬂow chart. CBS indicates chart-based support; DSS, decision support systems; MITT,
modiﬁed intention to treat; PHC, primary health care center.
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tion arm was 741, that is, a total of 8 clusters (with equal
cluster size of 100 each) was required per intervention arm
(Table 1).
Sampling Techniques
The average distance of the 84 PHCs in Mahabubnagar
district from the nearest secondary level of care, the
community health center (CHC), was 20 km. We stratiﬁed
the 84 PHCs into two groups (1) less than 20 km from the
nearest CHC and (2) more than or equal to 20 km away from
the nearest CHC. A line listing of all PHCs was done in both
the groups. A random double-digit number table was used, by
an independent statistician not belonging to the study group,
to randomly choose 8 PHCs from the “less than 20 km
distance” group. Matched pairs of PHCs based on population
size were then created. Simple randomization by an indepen-
dent statistician was then used to distribute the paired PHC
into any one of the randomisation arms (ie, either DSS or CBS
intervention arms). Similar steps were repeated for the “more
than 20 km distance” group. Hence, 4 PHCs from the less
than 20 km group and 4 PHCs from the more than 20 km
group were randomized to receive DSS. Four PHCs (popula-
tion matched to those PHCs that entered DSS arm) from the
less than 20 km group and 4 PHCs from the more than 20 km
group (population matched to those PHCs that entered the
DSS arm) were randomized to receive CBS. Only those
assessing outcomes were blinded. Figure 2 depicts the
randomization arms and the randomization process adopted
for the study.
Table 1. Sample-Size Calculations for the Cluster Randomized Trial
Detectable
Difference in
SBP Between
Both the Groups
80% Power With an ICC of 0.02 90% Power With an ICC of 0.02
Sample Size
Required for
Individual
Rand Per Arm
Sample Size
Required for
Cluster Rand per
Arm (DE=2.98)
Sample Size
Required for
Cluster Rand With
CV=0.25 (DE=3.1)
Min no of
Clusters With
a Cluster Size
of 100
Sample Size
Required for
Individual
Rand Per Arm
Sample Size
Required for
Cluster Rand
Per Arm
(DE=2.98)
Sample Size
Required for
Cluster Rand
With CV=0.25
(DE=3.1)
Min No. of
Clusters With
a Cluster Size
of 100
4 mm Hg 374 1115 1160 24 500 1490 1550 32
5 mm Hg 239* 713* 741* 16* 320 954 992 20
6 mm Hg 166 495 515 12 222 622 689 14
CV indicates coefﬁcient of variation; DE, design effect; ICC, intracluster correlation.
*Sample size that was chosen for this study.
More than 20km from the nearest 
CHC secondary level of health care
Less than 20km from the nearest 
CHC secondary level of health care
PHC 1 PHC 2
DSS* CBS**
PHC 1 PHC 2 PHC 1 PHC 2
DSS CBS
PHC 1 PHC 2  
n = 107 n = 112
  
n = 99 n = 105
PHC 3 PHC 4 PHC 3 PHC 4
  
n = 149 n = 70
  
n = 100 n = 97
PHC 3 PHC 4 PHC 3 PHC 4
n = 98 n = 96 n = 92 n = 102 n = 105 n = 108 n = 96 n = 102
Physician DSS Physician CBS Physician DSS Physician CBS
* DSS – Decision Support System; ** – Chart Based Support; # PHC – Primary Health Care Centre      CBS         
**Recruitment period: Oct 2011 – March 2012; **Follow up for 12 months: until end March 2013
Figure 2. Randomization procedure followed during the study. CBS indicates chart-based support; CHC,
community health center; DSS, decision support systems; PHC, primary health care center.
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Study Procedures
The full details of the study procedures have been published
previously in the study protocol.14 Baseline data collection
included demographic variables, such as age, gender, resi-
dence, total household members, religion, marital status,
education level, employment status, occupation, and total
household income per year. Data on known cardiovascular
risk factors, such as type and quantity of smoking tobacco
(cigarette or locally consumed products, such as beedi,
chillum, and/or hukkah); type and quantity of oral tobacco
and consumption of smokeless tobacco manufactured prod-
ucts (indigenous and locally consumed products, such as
chewable tobacco, gutka, and paan with tobacco); and
number of days alcohol was consumed in a typical week,
whether alcohol was consumed regularly (deﬁned as con-
sumption of alcohol on more than or equal to 10 days in a
month) were collected at 0, 6, and 12 months after study
entry. The number of days in a week wherein physical activity
was undertaken as a part of daily activity or leisure sport
activity for 30 minutes a day was also collected. Dietary
history questions were restricted to number of times of daily
intake of salty food (locally high-salt prevalent food items,
such as pickles and papad), portions of fruits or vegetables
consumed per day, quantity oil and fat consumed by the
family members in a month, and type of oil/fat consumed by
the family in a month were collected at 0, 6, and 12 months
after study entry. Participants were explained that a portion
could be any one of the following: 1 portion of vegetables
(fresh, raw, tinned, or frozen)=3 tablespoons; salad, 1
portion=1 bowl; fresh fruit, 1 portion=1 medium apple, 1
banana; fruit juice (excluding cordials, fruit drinks, and
squashes); and 1 portion=1 small glass. Duration of HTN
since ﬁrst diagnosed, whether on current hypertensive
medications, presence or absence of any physician certiﬁed
comorbid conditions, such as peripheral vascular diseases,
kidney disease, diabetes mellitus, HF, cerebrovascular dis-
ease, myocardial infarction, arthritis, chronic obstructive
pulmonary disease, and asthma were collected under medical
history at 0, 6, and 12 months after randomization.
Measurements
Physical measurements, such as height, weight, waist
circumference, pulse, and BP, were measured by a digital
BP monitor at 0, 6, and 12 months after study entry. Care was
taken to ensure that all the PHCs had the same equipment
make, type, and validation procedures.
BP and pulse measurement
All BP measurements were taken by the physician in a
standardized way using digital BP equipment (automatic
digital BP monitor, Omron model HEM-7203; Omron Corpo-
ration, Kyoto, Japan). The HEM-7203 model was a validated
one with an accuracy of 3 mm Hg. BP was measured on the
right upper arm in the sitting position, after a rest of
5 minutes. Using an appropriate-sized cuff connected to a
digital device, and the same arm at a similar time of day, two
measurements were taken at 5-minute intervals. Instructions
were be given to the physicians to ensure that the lower edge
of the bladder be placed 2 to 3 cm above the position of
maximal pulsation of the brachial artery in the arm, just above
the antecubital fossa. Care was taken to ensure that the cuff
ﬁt ﬁrmly, was comfortabe, and was well secured. The mean of
the 2 readings were used for analysis.
Pulse measurements
Pulse measurements were recorded by the digital BP equip-
ment (automatic digital blood pressure monitor, Omron model
HEM-7203; Omron Corporation), after a rest of ﬁve minutes.
The digital BP equipment records the SBP, DBP, and the pulse
in the same sitting, which was then recorded. The average of
the two readings was used for the analysis.
Height, weight, and waist circumference
measurements
Participants were weighed in light indoor clothing with a
digital weighing machine (patient weighing scale, mechanical
[Seca Nera Big; Seca, Hamburg, Germany] model with 150-kg
capacity) with 100-g accuracy, which was standardized across
all the centers. Height was measured in bare feet with a 2-m
wall-mounted stadiometer. Waist circumference was mea-
sured on bare skin at the narrowest part of the abdomen
between the ribs and the iliac crest, as seen from the anterior
aspect, with a nonstretch metallic tape because this tech-
nique was documented to be least invasive and more
culturally appropriate.
Training for Health Care Staff on DSS and HTN
Management
Trainings were given to each PHC staff member during
delivery of the study equipment. Centers randomized to
receive CBS received trainings centered around the four key
elements: staging of BP; risk stratiﬁcation; drug algorithms;
and follow-up schedule and lifestyle advice (the same
elements of the DSS, but in the form of a ready-made
poster). Centers randomized to receive DSS were trained on
handling of netbooks, date entry, safekeeping procedures for
the equipment, data archival and data entry, data export
(excel and .csv formats), data synchronization with server
(where Internet access was available), and data archival
procedures (where no access to Internet) as well as the
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interpretation of the ﬁnal page summary and recommenda-
tions.
Pilot Testing of the Questionnaire (Data
Collection Form)
A questionnaire was developed with validated questions
adapted from published recent Indian studies.22 The ques-
tionnaire was translated into the local language (Telugu) and
back-translated by 2 independent translators. A third reviewer
compared the translated and back-translated versions. The
ﬁnalized questionnaire was ﬁeld tested in 10% of the
proposed sample size for cultural appropriateness. Questions
deemed to hurt cultural sensitivity were modiﬁed based on
pilot test results.
Study Recruitment
The average outpatient department (OPD) load was 50 to
100 patients per day in most centers. All consecutive patients
suffering from physician-certiﬁed HTN who were reporting to
the OPD of the PHC were recruited. One to 2 hypertensive
patients were recruited per day by the physician, per PHC,
from the patients attending the outpatient clinic in the PHC.
The average time for recruitment was approximately 4 to
8 patients per week per PHC and 16 to 32 per month per
PHC. Hence, in approximately 4 to 6 months, all the required
patients were recruited for the study from each center. Study
recruitment lasted from October 2011 to March 2012. A 12-
month follow-up phase for all recruited patients ended in
March 2013. Patients were followed up for 1 year from the
time they entered the study. Data collection using question-
naires on personal and dietary habits, risk factors, and
physical measurements were done at baseline and during the
6th and 12th month after study entry. Baseline and end of
12th-month comparisons were done for the primary endpoint.
The assessments at 0-, 6-, and 12-month time points were
integrated with their monthly visits to the PHCs (PHCs provide
medications on a monthly basis).
Ethical Consent Procedures
The study protocol was approved by the (1) Human Biology
Research Ethics Committee, University of Cambridge, UK, and
(2) Institutional Ethics Committee, Public Health Foundation of
India, New Delhi, India. Participants were given sufﬁcient time
to understand the contents of the patient information sheet,
which contained details on the study purpose, duration, study
procedures, right to withdrawal from the study, details of
patient conﬁdentiality, ethical committee clearances, and the
study team contact details. Participants were encouraged to
ask questions regarding any aspects of the study procedures
that they have not understood. The written informed consent
form was read out aloud in the native language to the study
participants. They were given an opportunity to seek clariﬁca-
tions on any issues that were not understood. Signatures were
obtained by the physician who was recruiting the hypertensive
patients for the study. The physician also signed and dated the
informed consent form. One copy was given to the patients
and 1 copy was retained at the study site. Written informed
consent was obtained from both the representatives of the
cluster (medical ofﬁcer in charge of the PHC) and individual
cluster members (hypertensive patients), and consent was
sought before randomization.
Cost-Effectiveness Analysis
Drummond’s 10-point check list for cost-effectiveness analy-
sis23 was used as a benchmark for our cost-effective analysis
(CEA). A societal perspective was employed because this
would enable the tangible costs to be directly compared
between both the intervention arms. The physician services,
hospital services, drugs, costs of the DSS software develop-
ment, and costs for charts (posters, etc.) involved in delivery
of health care were included in the direct health care costs.
Transportation to and from the site of care were included in
the indirect costs. The time horizon for the costs involved was
for a 1-year duration. Costs were discounted at 3%. Quantities
and unit prices for each item were calculated in Indian
National Rupees and U.S. dollars. Costs for human resources
were estimated from within the study. The building mainte-
nance costs, telephone, electrical, vehicle, and other capital
costs were sourced from published costing studies done
among PHCs in India.24
Cost-Effectiveness Ratio
A comparison of costs in monetary units with outcomes in
quantitative nonmonetary units was done in the CEA.
Resources required for intervention and values attached to
those resources and effects of treatment (either beneﬁt or
harm) and values attached to those effects for both the
groups were compared to determine the cost-effectiveness
ratio (CER). CERs were derived as the cost of the intervention
per mm reduction in SBP for both the DSS and CBS groups.
Sensitivity Analysis
The hardware equipment costs in the DSS intervention arm
are expected to fall with time and increase in usage. The
software costs would also reduce given that they would
entail no development, but only maintenance costs in the
future. Owing to the fact that DSS intervention per se costs
form a signiﬁcant proportion of costs, we performed a
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sensitivity analysis at 50% and 80% reduction in DSS
equipment costs.
Statistical Analysis Plan
Linear mixed-regression modeling was used to test the
hypothesis about difference in mean SBP levels over time
by trial group (interventions arms: DSS or CBS), accounting
for clustering of observations within centers and individuals
over time, using a random-effects model. Mean difference in
change in SBP and DBP (95% conﬁdence interval [CI]) between
the baseline and 12th month, for both intervention arms, were
reported as unadjusted values. The SBP and DBP difference in
changes from baseline between DSS and CBS groups at 12th
month of follow-up were adjusted for age, gender, height,
waist, body mass index (BMI), alcohol intake, pickle and papad
intake, and portions of vegetable/fruit consumed per day and
allowing for clustering of observations within centers and
individuals. The linear mixed-modeling approach included all
data available on participants, and the between trial group
comparisons correspond to modiﬁed intention to treat (mITT)
analyses. We performed an mITT, wherein we excluded those
patients who were randomized, but had not received the
allocated intervention in our analysis (randomized, but not
received the allocated intervention: 5 of the 845 patients in
the DSS arm and 10 of 793 in the CBS arm). We excluded the
patients who had not received the allocated intervention from
our analysis since we did not collect their data at 6th and
12th month time points (only baseline data collected). We
acknowledge this as a limitation in our analysis plan.
Additionally, we performed ITT by including both types of
missing data: (1) the patients who were lost to follow-up after
randomization and (2) patients who were randomized, but had
not received the intervention (5 and 10 patients in the DSS
and CBS groups, respectively). We have conducted further
sensitivity analysis by assuming the worst-case scenario for
patients lost to follow-up (no improvement in BP in the DSS
group and a reduction of at least 5 mm Hg in the CBS group).
A limitation of our study is that we have not adjusted the
alpha for secondary endpoints (lifestyle and dietary changes
and BP under control and cost comparisons) analysis.
Results
During the recruitment phase, which lasted from October 2011
to March 2012, 2478 consecutive HTN patients were observed
at the OPDs of the study centers and assessed for eligibility to
participate in the trial. A total of 521 did not ﬁt our eligibility
criterion (age greater than 64 years: 310; hospitalized within
the last 12 months: 162; pregnant and lactating females: 24;
and participants with a history of physician certiﬁed cancer:
25). Response rate was 83.6% (of 1957 eligible patients, 319
had declined to participate). Tables 2 and 3 summarize the
baseline features of patients randomized to the 2 groups.
There were no signiﬁcant differences in age, age category (3
age categories: 35 to 44; 45 to 54; and 55 to 64 years),
gender, religion, education, smoking status at baseline, and
prevalence of pre-existing HTN status between the 2 groups.
The treating physicians who were randomized to receive the
DSS agreed with the DSS recommendations and implemented
the suggested DSS recommendations in more than 93% of
patients at both 0- and 12-month time points (at 0 months:
agreed with and implemented DSS in 794 and 787 patients,
respectively, of 845 patients at baseline; at 12th month:
agreed with and implemented DSS in 747 and 742 patients,
respectively, of 781 patients at 12 months).
Comparison of Unadjusted SBP at 0 and
12 Months (Within Group)
Statistically signiﬁcant differences were found in the DSS arm
when unadjusted mean SBP (139.9; 95% CI: 135.1 to 144.8)
at the 12th month was compared to the unadjusted mean SBP
(151.1; 95% CI: 146.9 to 155.3) at 0 months (P<0.001).
Signiﬁcant differences were not found in the CBS arm when
unadjusted mean SBP (144.7; 95% CI: 140.7 to 148.9) at the
12th month was compared to the unadjusted mean SBP
(148.2; 95% CI: 143.3 to 153) at 0 months (P=0.0670).
Comparison of Unadjusted DBP at 0 and
12 Months (Within Group)
Statistically signiﬁcant differences were found in DSS arm
when unadjusted mean DBP (84.3; 95% CI: 82.0 to 86.5) at
the 12th month was compared to the unadjusted mean DBP
(89.7; 95% CI: 87.7 to 91.7) at 0 months (P<0.001).
Signiﬁcant differences were not found in the CBS arm when
unadjusted mean DBP (86.3; 95% CI: 84.6 to 87.9) at the 12th
month was compared to the unadjusted mean DBP (88.4; 95%
CI: 85.9 to 90.8) at 0 months (P=0.06).
Comparisons Between the DSS and CBS Arms
The unadjusted (without covariate adjustments, but allowing
for clustering of observations within centers and individuals)
mean difference in SBP change from baseline between DSS
and CBS groups at 12 months was 7.11 mm Hg (95% CI:
13.11 to 2.23 mm Hg; P=0.008). The unadjusted mean
difference in DBP change from baseline between DSS and
CBS groups at 12 months was 3.29 mm Hg (95% CI: 6.32
to 0.87 mm Hg; P=0.041). The mean difference in SBP
change from baseline between the DSS and CBS groups at the
12th month, adjusted for age, gender, height, waist, BMI,
alcohol intake, pickle and papad intake, and portions of
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vegetable or fruit consumed per day was 6.59 mm Hg (95%
CI: 12.18 to 1.42 mm Hg; P=0.021). The mean difference
in DBP change from baseline between the DSS and CBS at the
12th month, adjusted for age, gender, height, waist, BMI,
alcohol intake, pickle and papad intake, and portions of
vegetable/fruit consumed per day between both the groups
was 2.83 mm Hg (95% CI: 5.78 to 0.13 mm Hg;
P=0.083). The chosen variables to adjust for differences
between the 2 groups were based on the baseline data
differences between CBS and DSS groups, systematic liter-
ature review performed by our group, and other articles (from
India) that reported on the associations between the covariate
(s) and HTN.25–36 Table 4 and Figure 3 show the unadjusted
and adjusted mean difference in SBP and DBP change from
baseline between DSS and CBS groups at 6 and 12 months.
Comparison of BP Under Control
Figure 4 depicts the number of individuals who had their BP
under control in both the groups at 0 and 12 months. The
CBS group did not show an improvement in BP control,
Table 2. Baseline Features for CBS and DSS Groups
Variable
CBS Group
N (%) or
Mean (SD)
DSS Group
N (%) or
Mean (SD)
Gender
Male % (n) 409 (51.58) 419 (49.41)
Female 384 (48.42) 426 (50.41)
Age category
35 to 44 years 117 (14.75) 126 (14.91)
45 to 54 years 262 (35.04) 254 (30.08)
55 to 64 years 414 (52.21) 465 (55.03)
Education
None 390 (52.56) 457 (54.08)
Primary (1 to 4 years
of school education)
190 (25.61) 227 (26.86)
Secondary (5 to
12 years of school
education)
116 (15.63) 110 (13.02)
Above secondary 46 (6.20) 51 (6.04)
Marital status
Married 648 (86.98) 740 (87.57)
Single 18 (2.42) 6 (0.71)
Divorce 1 (0.13) 2 (0.24)
Widow 67 (8.99) 96 (11.36)
Cohabitation (live in
partner)
11 (1.48) 1 (0.12)
Employment status
Currently employed 113 (15.48) 150 (17.75)
Unemployed 457 (62.60) 558 (66.04)
Retired 17 (2.33) 23 (2.72)
Unemployment
benefits
143 (19.59) 114 (13.49)
Occupation
Housewife 217 (29.73) 227 (32.78)
Skilled manual
worker
52 (7.12) 37 (4.38)
Unskilled manual 159 (21.78) 117 (20.95)
Owner of business 11 (1.51) 27 (3.20)
Office worker 18 (2.47) 25 (2.96)
Self-employed
professional
29 (3.97) 24 (2.84)
Farmer 244 (33.42) 243 (28.76)
Household income per year
Less than Rs 24 000 311 (42.78) 324 (38.34)
Between Rs 24 000
and Rs 50 000
232 (31.91) 260 (30.77)
Between Rs 50 001
and Rs 10 000
142 (19.53) 187 (22.13)
Continued
Table 2. Continued
Variable
CBS Group
N (%) or
Mean (SD)
DSS Group
N (%) or
Mean (SD)
Between Rs 100 001
and Rs 200 000
32 (4.40) 46 (5.44)
Between Rs 200 001
and Rs 400 000
10 (1.38) 23 (2.72)
Height, cm 151.13 (10.48) 158.15 (9.97)
Weight, kg 60.64 (11.80) 61.41 (10.55)
Waist, inches 33.99 (4.11) 36.99 (5.04)
BMI 26.52 (4.53) 24.54 (3.66)
SBP 148.01 (15.86) 151.03 (16.06)
DBP 88.31 (10.19) 89.44 (9.26)
Age, y 53.50 (7.78) 53.93 (7.77)
HTN duration in years 3.79 (3.69) 3.64 (4.1)
Prevalence of pre-
existing HTN
634 (79.9%) 666 (78.82%)
Number of patients on
more than 3
medications
24 (3.7%) 19 (2.8%)
BP
Stage 2 64 (8.1%) 58 (6.8%)
Stage 3 29 (3.3%) 24 (2.8%)
BP stage 2: SBP in between 160 and 179 mm Hg and DBP <110 mm Hg; BP (OR) DBP in
between 100 and 109 mm Hg and SBP <180 mm Hg; BP stage 3: SBP ≥180 mm Hg or
DBP ≥110 mm Hg. BMI indicates body mass index; BP, blood pressure; CBS, chart-
based system; DBP, diastolic blood pressure; DSS, decision support system; HTN,
hypertension; Rs, rupees (Indian currency); SBP, systolic blood pressure.
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whereas the DSS group signiﬁcantly improved BP control from
12.6% at baseline to 40.8% at the end of the study (P<0.001).
Comparison of Lifestyle and Dietary Factors
Between CBS and DSS Arms
Table 5 shows the comparison of lifestyle and dietary factors
between CBS and DSS at the 12th month. Signiﬁcant
differences were noted between the CBS and DSS groups at
the 12th month for current smokers (13.2% vs. 9.9%),
nonsmokers (67.6% vs. 75.3%), consumption of alcohol more
than or equal to less than once a week (26.5% vs. 20.9%),
taking part in physical activity at least 5 or more times in a
week for at least 30 minutes a day (87.4% vs. 94%), intake of
pickle less than once a week (77.3% vs. 47.2%), usage of ghee
(13.1% vs. 7.3%), and consumption of 2 or more portions of
vegetables/fruits per day (12.1% vs. 42.5%).
Loss to Follow-up
A difference in loss to follow-up was noticed between DSS
(845 patients at baseline, 64 patients lost to follow-up at
Table 3. Baseline Comparisons: Lifestyle and Dietary
Features
CBS Group: N (%) DSS Group: N (%)
Smoking status
Yes, he/she currently smokes 147 (18.85) 125 (14.79)
Yes, but he/she no longer
smokes
100 (12.82) 121 (14.32)
No 533 (68.33) 599 (70.89)
Cigarettes
1 to 5 per day 12 (37.50) 20 (60.61)
6 to 10 per day 9 (28.13) 8 (24.24)
>11 per day 11 (34.38) 5 (15.15)
Beedies
1 to 5 per day 46 (53.49) 38 (51.35)
6 to 10 per day 8 (9.30) 19 (25.68)
>11 per day 32 (37.21) 17 (22.97)
Oral tobacco
Chewable tobacco 42 (53.16) 45 (41.28)
Gutka 19 (24.05) 62 (56.88)
Paan with tobacco 18 (22.78) 2 (1.83)
Alcohol
7 days in a week 84 (10.81) 49 (5.80)
5 to 6 days in a week 57 (7.34) 15 (1.78)
2 to 4 days in a week 60 (7.72) 56 (6.63)
Once per week 105 (13.51) 92 (10.89)
Less than once a week 64 (8.24) 98 (11.60)
Don’t drink 407 (52.38) 535 (63.31)
Physical activity
At least 5 times a week 264 (33.29) 270 (31.95)
3 to 4 times a week 145 (18.28) 187 (22.13)
Less than 3 times a week 182 (22.95) 259 (30.65)
Never 152 (19.17) 92 (10.89)
Don’t know 49 (6.18) 37 (4.38)
Sports
At least 5 times a week 9 (1.13) 15 (1.78)
3 to 4 times a week 38 (4.79) 22 (2.60)
Less than 3 times a week 23 (2.90) 60 (7.10)
Never 595 (75.03) 630 (74.56)
Don’t know 128 (16.14) 118 (13.96)
Never 595 (75.03) 630 (74.56)
Don’t know 128 (16.14) 118 (13.96)
Pickle
Daily for every meal 14 (1.86) 28 (3.31)
Once daily 84 (11.17) 232 (27.46)
At least 3 to 4 times in a week 103 (13.70) 213 (25.21)
Continued
Table 3. Continued
CBS Group: N (%) DSS Group: N (%)
Less than once a week 551 (73.27) 372 (44.02)
Oil/fat consumed in a month
250 to 500 mL 3 (0.41) 6 (0.71)
500 mL to 1 L 2 (0.27) 29 (3.43)
1 to 1.5 L 693 (94.80) 720 (85.21)
1.5 to 2 L 0 (0) 63 (7.46)
More than 2 L 33 (4.51) 27 (3.20)
Oil/fat often used for cooking
Desi ghee 45 (6.07) 25 (2.96)
Ghee 83 (11.20) 71 (8.40)
Oil 379 (51.15) 387 (45.80)
Butter 72 (9.72) 157 (18.58)
Dalda 162 (21.86) 204 (24.14)
Vanaspati 0 (0) 1 (0.12)
Vegetables and fruits consumed per day
Less than 1 portion in a day 485 (66.35) 468 (55.38)
1 portion in a day 151 (20.66) 234 (27.69)
2 portions in a day 28 (3.83) 77 (9.11)
3 portions in a day 61 (8.34) 44 (5.21)
4 portion in a day 3 (0.41) 21 (2.49)
More than 4 portions in a day 3 (0.41) 1 (0.12)
CBS indicates chart-based system; DSS, decision support system.
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12th month; loss=7.5%) and CBS (793 patients at baseline, 7
patients lost to follow-up at 12th month; loss ≤1%) arms at
the end of 12 months of follow-up. To address the discrep-
ancy in the loss to follow-up rates between both arms, we
conducted further sensitivity analysis by imputing the
missing data assuming a worst-case scenario (no improve-
ment in BP in the DSS group and a reduction of at least
5 mm Hg in the CBS group). The trend for the results
remained unchanged in the worst-case scenario (unadjusted
SBP change [95% CI] from baseline to 12 months was 8.09
[11.17, 4.92] mm Hg in DSS vs. 4.10 [7.33,
1.56] mm Hg in CBS).
ITT Analysis
Upon inclusion of the patients who were randomized but had
not received the intervention (5 and 10 patients in the DSS
and CBS arms, respectively), and by imputing the missing
values assuming the worst-case scenario for patients lost to
follow-up, the mean difference in SBP change from baseline
between the DSS and CBS at 12th month was –4.54 mm Hg
(95% CI: 5.89 to 3.18 mm Hg; P=0.013) and the mean
difference in DBP change from baseline between the DSS and
CBS at the 12th month was 1.89 mm Hg (95% CI: 2.74 to
1.03 mm Hg; P=0.01).
Stratiﬁed Analysis of Primary Outcome Based on
Stage of BP
In the DSS group, at the study beginning, the proportion of
patients having BP under control (SBP <140 mm Hg and DBP
<90 mm Hg), stage 1 BP (SBP 140 to 159 mm Hg or DBP 90
to 99 mm Hg), stage 2 BP (SBP 160 to 179 mm Hg or DBP
100 to 109 mm Hg), and stage 3 BP (SBP >180 mm Hg or
DBP >110 mm Hg) was 12.6%, 60.02%, 21.2%, and 6.06%
(106, 503, 178, and 51 patients). At the study end, the
proportion of patients having normal, stage 1, stage 2, and
stage 3 BP had changed to 40.7%, 52.19%, 5.4%, and 0.7%,
respectively (307, 393, 47, and 6 patients). In the CBS group,
at the study beginning, the proportion of patients having
normal BP, stage 1, stage 2, and stage 3 BP was 23.7%,
47.6%, 21.8%, and 6.7%, respectively (186, 373, 171, and 53
patients). At the study end, the proportion of patients having
normal, stage 1, stage 2, and stage 3 BP had changed to
22.9%, 64.03%, 10.7%, and 2.3%, respectively (178, 495, 83,
and 18 patients).
Table 4. SBP and DBP Difference in Changes From Baseline Between DSS and CBS Groups at 6th and 12th Month of Follow-up
Variable Trial Arm Month
Difference (95% CI) vs. Baseline
for Each Randomized Group P Value
Difference (95% CI) in Changes
From Baseline Between Trial Arms P Diff Value
(A) Without covariate adjustments
Difference in SBP CBS 6 2.57 (7.98 to 3.58) 0.39 Ref —
Difference in SBP DSS 6 7.5 (12.23 to 2.31) 0.003 5.01 (11.74 to 1.69) 0.131
Difference in SBP CBS 12 4.11 (6.79 to 0.87) 0.06 Ref —
Difference in SBP DSS 12 11.42 (14.93 to 7.12) <0.001 7.11 (13.11 to 2.23) 0.008
Difference in DBP CBS 6 0.92 (3.84 to 2.1) 0.71 Ref —
Difference in DBP DSS 6 6.78 (8.12 to 3.21) <0.001 5.71 (9.79 to 2.34) 0.005
Difference in DBP CBS 12 2.79 (4.91 to 0.22) 0.048 Ref —
Difference in DBP DSS 12 5.02 (7.94 to 3.39) <0.001 3.29 (6.32 to 0.87) 0.041
(B) Adjusted for covariates
Difference in SBP CBS 6 2.11 (7.24 to 3.02) 0.40 Ref —
Difference in SBP DSS 6 6.42 (11.12 to 1.29) 0.027 4.19 (11.21 to 2.88) 0.30
Difference in SBP CBS 12 3.59 (7.71 to 0.12) 0.061 Ref —
Difference in SBP DSS 12 10.13 (14.24 to 6.45) <0.001 6.59 (12.18 to 1.42) 0.021
Difference in DBP CBS 6 0.71 (3.0 to 2.07) 0.72 Ref —
Difference in DBP DSS 6 5.97 (8.57 to 3.92) <0.001 5.23 (9.11 to 1.47) 0.003
Difference in DBP CBS 12 2.82 (4.72 to 0.97) 0.06 Ref —
Difference in DBP DSS 12 5.09 (7.64 to 2.97) <0.001 2.83 (5.78 to 0.13) 0.083
Without covariate adjustments allows for clustering of observations within centers and individuals; covariates included: age, gender, height, waist, BMI, alcohol, pickle intake, vegetable/
fruit intake; P value=P value for difference (95% CI) vs. baseline for each randomized group; P diff value=P value for difference (95% CI) in changes from baseline between trial arms. CBS
indicates chart-based system; CI, conﬁdence interval; DBP, diastolic blood pressure; DSS, Decision support system; SBP, systolic blood pressure.
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Given that the proportion of patients having BP under
control varied between both the groups (12.6% in DSS vs.
23.7% in CBS), we performed a matched analysis. Upon
comparing the patients with BP under control at baseline, the
mean difference in SBP between both the CBS (N, mean [SD]:
186, 130.7 [7.3]) and DSS (N, mean [SD]: 106, 128.1 [1.0])
groups was 2.6 mm Hg (95% CI: 4.6 to 0.5; P=0.01),
which was signiﬁcantly higher in the CBS group. Upon
comparing the patients with BP under control at baseline, the
mean difference in DBP between both the CBS (N, mean [SD]:
186, 80.8 [5.3]) and DSS (N, mean [SD]: 106, 78 [8.9]) was
2.8 mm Hg (95% CI: 1.1 to 4.4; P=0.01), which was
signiﬁcantly higher in the CBS group. The baseline SBP mean
(SD) values in the CBS group for stage 1, 2, and 3 (n=373,
168, and 53 patients, respectively) was 146.2 (7.2), 163.1
(11), and 173.8 (17.9) mm Hg, respectively. Baseline SBP
mean (SD) values in the DSS group for stage 1, 2, and 3
(n=503, 178, and 51 patients, respectively) was 147.5 (6.8),
164.2 (9.2), and 186.7 (14.1) mm Hg, respectively. Baseline
DBP mean (SD) values in the CBS group for stage 1, 2, and 3
were 86.5 (7.2), 94.8 (8.3), and 107.4 (10.1) mm Hg,
respectively. Baseline DBP mean (SD) values in the DSS
group for stage 1, 2, and 3 were 89.2 (5.6), 92.2 (8.1), and
105.3 mm Hg, respectively. There was no statistically signif-
icant difference in the baseline SBP values for stage 2
hypertensive patients between the groups (1.1 mm Hg, 95%
CI: 3.2 to 1.03; P=0.31); however, statistically signiﬁcant
difference in baseline SBP (between CBS and DSS groups)
was noted for patients who had their BP under control, and for
patients who were in stage 1 and 3 BP (1.3 mm Hg, 95% CI:
2.2 to 0.3, P=0.006; 12.9 mm Hg, 95% CI: 19.2 to
6.5, P<0.001, respectively).
Within-Group Comparison Between 0 and 12th
Month Based on Stages of BP
A 0- and 12th-month comparison was done to ﬁnd out the
mean change in SBP and DBP (within-group difference at 0-
and 12th-month readings) among all patients in the stage 1, 2,
and 3 BP categories. All patients suffering from BP stages 1 to
A B
C D
Figure 3. Mean blood pressure in randomized groups by month and differences versus baseline. CBS
indicates chart-based support; CI, conﬁdence interval; DBP, diastolic blood pressure; DSS, decision
support systems; SBP, systolic blood pressure.
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Figure 4. Comparison of CBS and DSS groups: BP under control
(SBP <140 and DBP <90 mm Hg). BP indicates blood pressure;
CBS, chart-based support; DBP, diastolic blood pressure; DSS,
decision support systems; SBP, systolic blood pressure.
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3 in the DSS group (n at 0 month=503, 178, and 51; n at 12th
month=460, 151, and 38, respectively) had a statistically
signiﬁcant change in mean SBP (stage 1: 147.5 [6.8] vs. 140
[8.5], P<0.001; stage 2: 164.1 [9.2] vs. 147.8 [12.2],
P<0.001; and stage 3: 186.7 [14.1] vs. 153.3 [16.8],
P<0.001) and DBP levels (stage 1: 89.1 [5.5] vs. 85.1 [6.3],
P<0.001; stage 2: 92.1 [8.1], 85.7 [6.7], P<0.001; and stage
3: 105.3 [12.9] vs. 87.69 [9.9], P<0.001) at the study end,
when compared with the baseline.
Patients suffering from BP stage 2 (n=167) in the CBS
group had a statistically signiﬁcant change in SBP (mean [SD]
at 0 and 12 months: 163.1 [11], 149.5 [12.6], P<0.001) and
Table 5. Comparison of Lifestyle and Dietary Factors
Between CBS and DSS at 12th Month
Variable
CBS at 12th
Month
DSS at 12th
Month
P ValueN % N %
Do you smoke, or have you ever smoked
Yes, he/she
currently
smokes
102 13.16 75 9.96 <0.001
Yes, but he/she
longer smokes
149 19.23 111 14.74
No 524 67.61 567 75.29
Cigarettes
1 to 5 per day 21 70.00 29 63.04 0.027
6 to 10 per day 8 26.67 11 23.91
>11 per day 1 3.33 6 13.04
Beedies
1 to 5 per day 57 58.76 50 62.50 0.001
6 to 10 per day 20 20.62 21 26.25
>11 per day 20 20.62 9 11.25
Alcohol
7 days in a week 51 6.76 27 3.59 <0.001
5 to 6 days in a
week
37 4.91 20 2.66
2 to 4 days in a
week
42 5.57 42 5.58
Once per week 70 9.28 68 9.03
Less than once
per week
32 4.24 91 12.08
Don’t drink 522 69.23 505 67.07
Physical activity
At least 5 times in
a week
339 43.63 282 37.45 <0.001
3 to 4 times in a
week
170 21.88 169 22.44
Less than 3 times
in a week
170 21.88 257 34.13
Never 94 12.10 32 4.25
Don’t know 4 0.51 13 1.73
Sport
At least 5 times in
a week
9 1.16 60 7.97 <0.001
3 to 4 times in a
week
53 6.82 72 9.56
Less than 3 times
in a week
52 6.69 46 6.11
Never 519 66.80 518 68.79
Don’t know 144 18.53 57 7.57
Continued
Table 5. Continued
Variable
CBS at 12th
Month
DSS at 12th
Month
P ValueN % N %
Pickle
Daily for every
meal
17 2.22 15 1.99 <0.001
Once daily 98 12.81 139 18.46
At least 3 to 4
times in a week
59 7.71 242 32.14
Less than once a
week
591 77.25 357 47.41
Oil/fat consumed
250 to 500 mL — — 2 0.27 <0.001
500 mL to 1 L 4 0.52 60 7.97
1 to 1.5 L 761 99.09 684 90.84
1.5 to 2 L — — 4 0.53
More than 2 L 3 0.39 3 0.40
Oil/fat often in cooking
Desi ghee 36 4.64 3 0.40 <0.001
Ghee 102 13.14 55 7.30
Oil 458 59.02 437 58.03
Butter 68 8.76 148 19.65
Dalda 112 14.43 110 14.61
Fruits and vegetables
Less than 1
portion
472 61.22 297 39.44 <0.001
1 portion 205 26.59 136 18.06
2 portion 49 6.36 195 25.90
3 portion 40 5.19 82 10.89
4 portion 3 0.39 31 4.12
More than 4
portions
2 0.26 12 1.59
CBS indicates chart-based system; DSS, decision support system.
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DBP (mean [SD] at 0 and 12 months: 94.8 [8.2], 88.2 [9.1]
P<0.001). Patients suffering from stage 3 BP in the CBS group
(n=52) had a statistically signiﬁcant change in SBP (mean [SD]
at 0 and 12 months: 173.8 [17.9], 153.3 [13.9], P<0.001) and
DBP (107.4 [10.1], 90.1 [10.4], P<0.001) at the study end,
when compared with the baseline. However, stage 1 BP
patients in the CBS (n=372) did not a show a statistically
signiﬁcant mean change in either SBP or DBP (mean SBP and
DBP [SD] at 0 and 12 month: SBP, 146.2 [7.1], 145.2 [11.3],
P=0.13; DBP, 86.52 [7.2], 86.03 [6.7], P=0.33).
Between-Group Comparison Between 0 and 12th
Month Based on Stages of BP
Among stage 1 BP patients, difference in mean SBP change
between the CBS and DSS group at the 12th month was
5.3 mm Hg (95% CI: 7.3 to 4.5; P<0.001). Among stage
2 BP patients, difference in mean SBP change between the
CBS and DSS group at the 12th month was 1.9 mm Hg
(95% CI: 5.1 to 1.2; P=0.22). Among stage 3 BP patients,
difference in mean SBP change between the CBS and DSS
group at the 12th month was –14.1 mm Hg (95% CI: 22.5
to 5.6; P<0.001).
Among stage 1 BP patients, difference in mean DBP
change between the CBS and DSS group at the 12th month
was 1.1 mm Hg (95% CI: 2.5 to 0.31 P=0.01). Among
stage 2 BP patients, difference in mean DBP change between
the CBS and DSS group at the 12th month was 4.6 mm Hg
(95% CI: 6.5 to 2.6; P<0.001). Among stage 3 BP patients,
difference in mean DBP change between the CBS and DSS
group at the 12th month was 16.1 mm Hg (95% CI: 21.1
to 10.93; P<0.001).
Cost Comparisons
In a usual care scenario, the direct and indirect costs put
together worked out to be $30 330 per year per PHC
(Table 6). Average unit cost estimates per outpatient visit
without drug or diagnostics (adjusted for inﬂation for the
years 2008–2012) were calculated to be $22.34. The total
costs for DSS intervention were $19 513 and the total costs
for CBS were $7510. Tables 7 and 8 provide the calculations
for the cost estimates for both the interventions. Brieﬂy, in the
DSS arm, the equipment cost was $2852.06 and development
and validation of DSS costs were $10 622.64, whereas in the
CBS arm equipment cost was $515.46 and poster and
stationary cost (data collection forms) was $956.6. Similar
costs were incurred for doctor compensation charges ($3018)
and patient travel compensation costs ($3018) in both the
groups. The cost per patient in the DSS arm was $370.48,
whereas the cost in the CBS arm per patient was $344.69
(Table 9).
Sensitivity Analysis for Costings
Equipment costs contributed a signiﬁcant proportion of DSS
costs. If equipment prices fall by 50%, estimated mean costs
per year for the DSS group would decrease from $19 513 to
$12 776. If equipment prices fall by 80%, the DSS mean costs
per year would be $8733 (less than 50% of total costs for DSS
intervention). However, total costs of the DSS group would
remain slightly higher than those of the CBS group (difference
of $1223). SDs for the equipment costs could not be
calculated owing to the fact that the procurement was
centralized and each center had the same model and make of
equipment.
Cost-Effectiveness Ratios
The average costs per patient for the CBS group patient
($344.69) divided by the average reduction in SBP over a 12-
month period (3.59 mm Hg) yielded a CER of $96.01 per mm
reduction in SBP for the CBS group; the corresponding CER
for DSS intervention arm was $36.57 ($370.48 divided by
10.13) per mm reduction in SBP.
Discussion
Our cluster randomized trial has shown that DSS help
physicians to undertake guideline-based risk staging, pre-
scribe appropriate drug therapy, provide follow-up advice, and
offer tailor-made counseling suggestions to patients based on
their lifestyle and dietary factors. The adjusted mean differ-
ence in systolic BP, at 12th month of follow-up, between the
DSS and CBS in our study was 6.59 mm Hg (95% CI:
12.18 to 1.42 mm Hg; P=0.021). The adjusted mean
difference in DBP, at 12th month of follow up, between the
DSS and CBS intervention arms was statistically not signif-
icant (2.83 mm Hg, 95% CI: 5.78 to 0.13 mm Hg,
P=0.083). Statistically signiﬁcant differences between base-
line and 12th month of follow-up have been found for both
SBP and DBP in the DSS arm. A trend toward statistical
signiﬁcance for both differences between baseline and 12th
month of follow-up in SBP and DBP was noted even in the CBS
arm (P values of 0.061 and 0.06, respectively). The CERs for
CBS and DSS groups ($96.01 and $36.57 per mm of SBP
reduction) are very cost-effective because they are less than
the per-capita gross domestic product of India ($1509; most
recent estimate from World Bank in 2011).
The magnitude of difference for SBP between the
intervention arms at study endpoint that has been found in
our study (6.59 mm Hg; 95% CI: 12.18 to 1.42 mm Hg)
has not been shown in any of the other DSS studies done
thus far in the developed world. This could have arisen owing
to 3 reasons. First, our cluster randomized study has been
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undertaken in a resource-limited PHC setting, wherein the
experience of the treating doctors and the health care staff
for management of BP on clinical guideline based manage-
ment is limited owing to the fact that the usual practice is to
refer all cases to second-tier health care (to the nearest CHC
for initial screening and management of all hypertensive
patients). Second, rigorous adherence of all sequential steps
in the DSS algorithm by all the participating physicians made
sure that risk, staging, history, and measurements were
followed up with tailor-made recommendations on drug
management and counseling for lifestyle support. Finally,
repeated counseling on lifestyle modiﬁcations at 0, 6, and 12
months by treating physicians and regular governmental
supply of quality antihypertensives may have yielded the
desired results.
Our study does not show a statistical signiﬁcance for the
adjusted mean difference in DBP, at 12th month of follow-up,
between the DSS and CBS in our study. This could have arisen
owing to various reasons. First, it has been documented, in
clinical trials, that restriction of salt intake results in greater
decrease in SBP than in DBP37,38 (restricting salt intake to
80 mmol daily reduces SBP by 4.3 mm Hg and DBP by
2 mm Hg39). Consumption of salty food reduced in both
groups at study end, when compared with baseline intake
(owing to the lifestyle counseling given at 0-, 6-, and 12-month
time points), and thus might explain the greater drop in SBP,
Table 6. Health System Costs for a 1-Year Time Period per PHC
Source INR Per Month
No. of Personnel
Per PHC/Units
Costs Per Year
(INR/Year)
US Dollars
Per ($/Year)
Personnel costs
(A) Recurrent costs
Physician salary/month Estimated within study 30 000.00 1.00 360 000.00 6792.45
Staff nurses Estimated within study 12 190.00 2.00 292 560.00 5520.00
Second ANMs Estimated within study 10 200.00 1.00 122 400.00 2309.43
Pharmacist Estimated within study 12 190.00 1.00 146 280.00 2760.00
Lab technician Estimated within study 9000.00 1.00 108 000.00 2037.74
Data entry operator Estimated within study 9500.00 1.00 114 000.00 2150.94
Health worker (female) Estimated within study 10 020.00 1.00 120 240.00 2268.68
Health assistant (male) Estimated within study 10 020.00 1.00 120 240.00 2268.68
Health assistant (female)/lady health
visitor
Estimated within study 9000.00 1.00 108 000.00 2037.74
Multiskilled Group D worker Estimated within study 6700.00 2.00 160 800.00 3033.96
Sanitary worker cum watchman Estimated within study 6700.00 1.00 80 400.00 1516.98
Accredited Social Health Activists (ASHA) Estimated within study 800.00 6.00 57 600.00 1086.79
Cost of consumables, electrical charges,
telephone charges, building maintenance,
vehicle charges
Published literature 6250.00 12.00 75 000.00 1415.09
Drugs—provided by the government 0.00 0.00 0.00 0.00
Laboratory—blood and urine—free 0.00 0.00 0.00 0.00
Total recurrent cost (Rs) 132 570.00 1 590 840 30 015.85
(B) Capital cost
PHC building depreciation Published literature 709.67 8516.00 160.68
Subcenter building depreciation (6) Published literature 368.89 4426.66 83.52
Furniture depreciation Published literature 282.31 3387.73 63.92
Electrical fitting depreciation Published literature 24.79 297.51 5.61
Vehicle depreciation Published literature 0.00 0.00 0.00
Total capital cost 1385.66 16 627.90 313.73
Total cost (A+B) 133 955.66 1 607 467 30 329.58
ANM indicates auxillary nurse midwife; INR, Indian National Rupees; PHC, primary health care center; US$, United States dollars.
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as compared to DBP, in both the study groups. Second,
changes in lifestyle and dietary habits, such as increased
physical activity, reduced alcohol consumption, and increased
consumption of fruits and vegetables, all of which are known
to lower SBP more than DBP,40–43 may have led to more SBP
reduction, as compared to DBP, in our study. Third, the
Table 7. Intervention Costs for DSS Group
Items Cost/Unit (INR) No. of PHCs Amount (INR) Amount (US$)
Equipment cost
Girth measuring tape 15 8 120 2.26
Height measuring scale, 2 m, wall mounted 450 8 3600 67.92
Patient weighing scale, mechanical, (Seca Nera Big, 150-kg capacity) 850 8 6800 128.30
netbook/notebook/laptop costs 15480 8 123 840 2336.60
Automatic digital blood pressure monitor (Omron HEM-7203) 2100 8 16 800 316.98
DSS, development cost 563 000 10 622.64
Patient travel compensation 160 000 3018.87
Doctor compensation and training costs 160 000 3018.87
Grand total 1 034 160 19 512.45
DSS indicates decision support system; INR, Indian National Rupees; PHC, primary health care center; US$, United States dollars.
Table 8. Intervention Costs for CBS Group
Items Cost/Unit (INR) No. of PHCs Amount (INR) Amount (US$)
Equipment cost
Girth measuring tape 15 8 120 2.26
Height measuring scale, 2 m, wall mounted 450 8 3600 67.92
Patient weighing scale, mechanical (Seca Nera Big, 150-kg capacity) 850 8 6800 128.30
Automatic digital blood pressure monitor (Omron HEM-7203) 2100 8 16 800 316.98
Patient travel compensation 160 000 3018.87
Poster charges 18 380 346.79
Doctor compensation and training costs 160 000 3018.87
Stationary (data collection forms) 30 070 567.36
Translation charges 2250 42.45
Grand total 398 020 7509.81
CBS indicates chart-based support; INR, Indian National Rupees; PHC, primary health care center; US$, United States dollars.
Table 9. Comparison of Total Costs Involved for Both Groups for 1 Year
Items DSS CBS
Health system cost in USD $242 637 ($30 330 per PHC; total for 8 PHCs) $242 637 ($30 330 per PHC; total for 8 PHCs)
Patient care costs, OPD health
care costs in USD
$16 822.02 ($22.34 for each patient;
total for 753 patients)
$17 335.84 ($22.34 for each patient;
for 776 patients)
Intervention costs in USD $19 512.45 (for 8 PHCs) $7509.81 (for 8 PHCs)
Total costs $278 971.79 $267 482.65
Cost per patient $370.48 $344.69
CBS indicates chart-based support; DSS, decision support systems; OPD, outpatient department; PHC, primary health care center.
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magnitude of within-group reduction in SBP at study end was
more than the magnitude of within-group reduction in DBP
(SBP: 10.13 mm Hg in the DSS group and 3.59 mm Hg in the
CBS group; DBP: 5.09 mm Hg in the DSS group and
2.82 mm Hg in the CBS group), which could have caused a
statistical signiﬁcant difference in SBP and an insigniﬁcant
difference in DBP between DSS and CBS groups at the 12th
month.
Strengths and Limitations
This study has several important strengths.
Blending within existing clinical work ﬂow: We followed the
SAGE (Standards-Based Sharable Active Guideline Environ-
ment) consortium project recommendations by developing a
DSS that has “a complex clinical guideline as a series of
recommendation sets.”44 Furthermore, we followed the SAGE
guidelines model, which suggests that DSS must seamlessly
blend within the clinical work ﬂow nonobtrusively and allow
for easy inspection of the underlying clinical logic, by having
“info” buttons displaying the logic behind the recommenda-
tions.44
Stakeholder involvement in DSS development process: A
validated and pilot-tested DSS was developed in resource-
constrained settings after extensive consultations and focus
group discussions with all stakeholders involved.
Reporting on patient outcomes: Computerised clinical DSS
(CCDSS) have reported an improvement in physician perfor-
mance and in quality of care given for patients, when CCDSS
were deployed in developed countries.3,13 Ours is the ﬁrst
study that has documented an improvement in patient-related
outcomes for managing HTN at a primary health care level in
low- and middle-income country settings (LMICs).
Multicomponent intervention with concurrent advice to
physicians and patients in institutional settings: A recent
review reported that system-initiated CCDSS in institutional
settings performed better than ambulatory settings.45 Our
DSS-HTN has been set up in PHCs, which are the ﬁrst gateway
for institutional health care provider services in India. Adding
a multicomponent intervention (clinical guidelines for the
physician and lifestyle counseling for the patients) has yielded
a comprehensive risk management strategy, thereby making
our DSS-HTN an effective tool for management of CVDs
among hypertensive patients. In a recent decision maker/
research partnership systematic review on CCDSS, transpar-
ent documentation of steps to clearly mention the design of
the system, context in which CCDSS are deployed, imple-
mentation process, costing involved, user satisfaction, and
impact on workﬂow patterns have been stated as key factors
that ensure success in development and implementation of
DSS.46 Our study has taken care to carefully delineate the
above-mentioned key factors.
Inclusion of cost-effective results: Very few DSS studies
from the developed world have reported on cost-effectiveness
parameters. We studied the costs and the effect-size gains
involved among both the interventions and have arrived at
reasonable estimates of accuracy (all our costs have been
based on WHO-CHOICE 200847 information, adjusted to
inﬂation for the years 2009–2012).
Our DSS-HTN study meets 4 of the top 5 key DSS services
and capabilities that have been listed in the consensus
assessment of the health level 7 clinical decision support
work group report.48 “Clinical data query service, user
communication service, use of appropriate and standard
information models and the ability to leverage the DSS,”
which were ranked on an absolute important scale,48 and are
the key services and capabilities needed for a service-oriented
architecture, are present in our DSS-HTN. Finally, we have
strived to provide recommendations, rather than mere
assessments, for the physician in his daily workﬂow pattern
at the time and location of his or her decision making, which
have been identiﬁed as independent predictors for improving
clinical practice when using CDSS.49
Our study has some potential limitations. First, our study
did not have a usual care (UC) group. The comparison of DSS
was done with the CBS group in our study. Given that the
quality of usual care is very low in PHC settings in India, the
ethical committee suggested having a chart-based support
system in place of UC, wherein the chart-based system
mimics all that is in a DSS, except that it is optional for the
physician to refer to the pocket guidelines in CBS, whereas
the physicians in the DSS group necessarily had to go step by
step using the software processes in the netbooks. Our
original intention to perform a cluster randomized trial with 3
arms—DSS, CBS, and UC—was not feasible in our settings
owing to limitations in budget, higher sample-size estimates,
and lack of ethical committee’s approval to undertake a 3-arm
study. Second, there was a considerable difference between
the 2 treatment groups with respect to the number of patients
with BP under control at baseline (186 participants in CBS and
106 in DSS). Having fewer patients with BP under control
could have allowed participants in the DSS group more
opportunity to improve BP. We attempted to overcome this
limitation by doing a subgroup analysis based on the stages of
BP. In the between-group comparison at baseline, a signiﬁcant
difference in SBP was noted for patients in stage 1 and 3 BP.
However, the between-group comparison at the 12th month
showed a signiﬁcant reduction in BP even after accounting for
between-group baseline differences. The mean difference in
SBP change from baseline between the DSS and CBS at the
12th month for patients in all stages of BP was signiﬁcantly
higher than the mean difference (between group) in SBP
values at baseline (stage, 12th-month difference versus 0-
month difference in SBP, stage 1: 5.3 vs. 1.3 mm Hg;
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stage 2: 1.9 vs. 1.1 mm Hg; stage 3: 14.5 vs.
12.9 mm Hg, respectively).
Third, a difference in loss to follow-up was noticed between
DSS (7.5%) and CBS (<1%) arms at the end of 12 months of
follow-up. To address the discrepancy in the loss to follow-up
rates between both the arms, we conducted further sensitivity
analysis by imputing the missing data assuming a worst-case
scenario, although we acknowledge that multiple imputation
may be a better approach for dealing with missing data on the
covariates as well. We used a linear mixed model for
inferences, which allowed the inclusion of all available data
from the participants at baseline and during follow-up in the
modeling. Furthermore, because the modeling allowed for
clustering at the center level and modeled the within-subject
correlations over time, the likelihood-based inferences would
have been unbiased under the missing-at-random assumption.
Fourth, a majority (90%) of the study-site population is rural
and this may have affected the generalizability of the ﬁndings
to urban areas in India. However, this may have a limited
impact given that 68.84% of the Indian population resides in
rural areas (Indian Census 2011 data).50 Moreover, because
our target was resource-constrained PHCs, we chose rural
settings. However, our study ﬁndings would be applicable to
primary care settings in other LMICs given that they, too,
suffer from similar problems, including lack of trained
manpower and deﬁcient health system infrastructure.
Finally, our study does not integrate the data from patient
electronic records and hospital clinical information systems
owing to the fact that the infrastructure for health management
information system is still at a very primitive stage in India. The
knowledge-based engine in our system, built mostly on “if and
then” scenarios, limits itself to management of HTN only at
primary care settings. Similarly, potential interactions with
other drugs that would have had an effect on BP have not been
built in the system. Referral scenarios are suggested when the
reasoning engine is confronted with complex data that can be
managed only at secondary and tertiary care settings.
Conclusion
DSS embedded with clinical practice guidelines aid imple-
mentation of evidence-based clinical practice guidelines for
management of HTN even in resource-limited settings. DSS
result in better management of HTN, provided patients adhere
to the suggested dietary and lifestyle modiﬁcations, and
medications and providers adhere to the suggested DSS
recommendations. Key features of the DSS include (1)
patient-speciﬁc, tailor-made, and guideline-based recommen-
dations on risk factors and disease management of HTN and
(2) counseling on lifestyle modiﬁcation, both of which aid the
end user (clinicians) to decide on the appropriate line of
management for the patient. The DSS was not only effective,
but also cost-effective in management of HTN. Future studies
on DSS should be of a longer duration and look at assessing
(1) the effectiveness of the intervention in reducing the
number of MI and stroke cases and (2) cost utility of the DSS,
which, when answered, would aid in deciding the scalability
and replicability of DSS in similar LMIC settings.
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SUPPLEMENTAL MATERIAL 
 
 
Table S1: Referral criteria to a higher secondary or tertiary health care center 
 
Referral criteria 
• History of heart disease (any history of heart attack, angina, heart failure, any surgical 
procedure on coronary vessels, i.e. CABG or PTCA) 
• History of stroke or Transient Ischemic attack 
• Co morbid diabetes and hypertension 
• History of Renal disease (renal failure - S. creatinine>2 mg/dl; or diabetic nephropathy) 
• History of vascular disease (peripheral arterial disease, eg, claudication; or aortic 
dissection) 
• Any evidence of LVH (on an ECG or an echocardiogram) 
• Any evidence of microalbuminuria or proteinuria and or elevation of serum creatinine 
(1.2-2.0mg/dl) 
• Any evidence of atherosclerotic plaques in the carotids (ultrasound or radiological) 
• Any evidence of hypertensive retinopathy 
• Any of the Physician certified co-morbid conditions such as PVD, Kidney disease, 
Diabetes, Heart failure, CVD, MI, Arthritis, COPD, Asthma 
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